F8 and hemophilia A: Focusing on the Phase 1/2 dose-escalation SPK 8011 clinical trial, with four dose cohorts ranging from 5x1011 vg/kg to 2x1012 vg/kg, 16 adult patients with hemophilia A showed sustained FVIII expression, with 12 patients followed-up for over 2 years [128].